-+ 0.00%
-+ 0.00%
-+ 0.00%

Amylyx to release Phase 3 LUCIDITY trial topline results for avexitide in post-bariatric hypoglycemia Aug. 18, 2026

PUBT·08/17/2026 20:01:31
Listen to the news
Amylyx to release Phase 3 LUCIDITY trial topline results for avexitide in post-bariatric hypoglycemia Aug. 18, 2026
  • Amylyx scheduled topline Phase 3 LUCIDITY results for avexitide in post-bariatric hypoglycemia on Aug. 18, 2026.
  • Results have not been presented yet; management plans an 8:00 a.m. ET conference call with an audio webcast.
  • The update is expected to clarify whether avexitide can meaningfully reduce hypoglycemia episodes in this patient group.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amylyx Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202608171601BIZWIRE_USPR_____20260817_BW660841) on August 17, 2026, and is solely responsible for the information contained therein.